ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2016.3961 ETM-0-0-3961 Articles The expression of insulin-like growth factor-1 in senior patients with diabetes and dementia ZhouYan-Ling 1 * LiuShu-Qing 2 * YuanBin 3 LuNing 4 Department of Neurology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264003, P.R. China Department of Neurology, Linglong Yingcheng Hospital, Zhaoyuan, Shandong 265400, P.R. China Department of Neurology, Affiliated Hospital of Heze Medical College, Heze, Shandong 274000, P.R. China Department of Geriatric Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264003, P.R. China Correspondence to: Dr Ning Lu, Department of Geriatric Medicine, Yantai Affiliated Hospital of Binzhou Medical University, 717 Jinbu street, Yantai, Shandong 264003, P.R. China, E-mail: ning_lu1@163.com

Contributed equally

 01 2017 06 12 2016 13 1 103 106 16052016 31102016 Copyright: © Zhou et al. 2016 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

This study was conducted to investigate the expression of insulin-like growth factor-1 (IGF-1) in elderly patients with diabetes and dementia and to analyze the expression mechanism. A total of 30 senior patients with diabetes and dementia (group A), 30 senior patients with dementia but no diabetes (group B), 30 senior patients with diabetes but no dementia (group C), and 30 healthy seniors (group D) were continuously selected. The ELISA method was used to test the level of serum IGF-1, β-amyloid peptide (Aβ) and the phosphorylation of immunohistochemical staining of microtubule associated protein (tau protein). Western blot analysis was utilized to test the level of prion protein (PrP), forkhead transcription factor O (FOXO) subfamily protein, p-PI3K and p-Akt. The levels of IGF-1, Aβ, tau protein positive rate, PrP, FOXO protein, p-PI3K, and p-Akt in group A were significantly higher than that in group B, which was higher than in groups C and D. The results between groups A and B, but not groups C and D, were statistically significant (P<0.05). IGF-1 was highly expressed in senior patients with diabetes and dementia. Thus, IGF-1 can adjust the expression of PrP and FOXO through p-PI3K/Akt pathway and further impact the formation of Aβ and tau protein, leading to dementia.

 insulin-like growth factor-1 diabetes dementia β-amyloid peptide microtubule associated protein prion protein forkhead transcription factor O and PI3K/Akt Introduction

Alzheimer's disease (AD) is related to age and is a neurodegenerative disease featuring progressive cognitive disorder and memory damage. Since diabetes can increase the risk of vascular dementia and AD, some scholars regard AD as another type of diabetes (1). Rasgon and Jarvik (2) found that cognitive disorders or AD incidence rates were 2- to 3-fold higher in patients with type 2 diabetes mellitus (T2DM) than those in control group. Thus, T2DM was found to be a risk factor in cognitive disorders among seniors. The main pathologic features of AD include senile plaques, neurofibrillary tangles, neuro-reduction and insulin neuro-transduction involved in its metabolic pathway (2).

Insulin-like growth factor-1 (IGF-1) is an important neurotrophic factor and its receptor IGF-1R is prevalently expressed in the nervous system (3). IGF-1 can impact the elimination of β-amyloid peptide (Aβ) and the phosphorylation of microtubule associated protein (tau), which is related to PI3K/Akt and MAPK/ERK1/2 signal pathways (4). Forkhead transcription factor O (FOXO) subfamily protein, an important downstream responsive molecule in IGF-1 signal pathway, is modified and adjusted by the post-translational modification in the PI3K/Akt pathway (5). Most studies conducted are centered on AD animal models while few involve in-clinic observation. Therefore, this study serves as a reference to clinical diagnosis and treatment by examining whether the IGF-1 expression in different groups of seniors is related to diabetes and AD, and the possible action mechanism.

 Patients and methods <sec> <title>Subject information

A total of 30 senior patients who were admitted to and diagnosed by our hospital with diabetes and AD (group A), 30 with AD but no diabetes (group B), 30 with diabetes but no AD (group C), and 30 healthy seniors (group D) were continuously selected from June 2013 to January 2016. The selection criteria for the study were: i) Age, ≥65; and ii) meet WHO's T2DM diagnosis standard and Chicago AD diagnosis standard, including pre-clinical phase and dementia phase. The exclusion criteria included: i) Serious diabetes complications, such as eye-ground retinal hemorrhage, diabetic kidney disease, diabetic foot, and cardiovascular and cerebrovascular diseases, such as ischemic stroke, head injury, history of surgery and cancer; ii) neuropsychiatric disorders, autoimmune diseases, severe anxiety and depression; and iii) non-compliant patient.

The present study was approved by the ethics committee of Yantai Affiliated Hospital of Binzhou Medical University. Informed consent was obtained from the patients or their families. There were 17 males and 13 females in group A; average age of 70.5±6.3; fasting blood sugar averaged 8.2±2.0 mmol/l; and the course of disease averaged 5.6±1.7 years. There were 16 males and 14 females in group B, and the average age was 71.7±6.5. There were 15 males and 15 females in group C; average age of 71.6±6.8; fasting blood sugar averaged 8.5±2.2 mmol/l; and the course of disease averaged 5.8±1.4 years. There were 16 males and 14 females in group D, and the average age was 71.5±6.3. The difference in gender and age among groups was not statistically significant (P>0.05).

 Study methods

We utilized the ELISA method to test the levels of serotonin IGF-1, Aβ and the phosphorylation of immunohistochemistry staining microtubule associated protein (tau protein). We utilized the western blot method to test the level of prion protein (PrP), FOXO subfamily protein, p-PI3K and p-Akt. ELISA kits were purchased from Sigma (St. Louis, MO, USA) and the procedures in the manual were followed during testing. The main procedures of the immunohistochemical (SP) staining method were producing peripheral mononuclear cells of paraffin through conventional steps, including dewaxing, gradient alcoholic dehydration, 3% H2O2 inactivation of peroxidase, antigen retrieval, closure, adding phosphorylated tau protein (pSer202) antibody (1:100; Wuhan Boster Biological Engineering Co., Ltd., Wuhan, China), negative control plus phosphate-buffered saline (PBS), at 4°C overnight, 5 times of 3-min PBS washing, adding biotin-marked antibody (Beijing ZS-Bio Co., Ltd., Beijing, China), 30-min at 37°C incubation, 5 times of 3-min PBS washing, DAB coloration, hematoxylin staining, conventional dehydration, transparency made by xylene, neutral balsam mounting, observation and capturing images under a microscope (Olympus, Tokyo, Japan). We continuously observed 3 sections, counted 4 non-overlap horizons randomly <400-fold enlarged horizon, and tested the ratio of the number of cells with positive response, which was stained pale brown, in each horizon. The averages were determined by using the Image-Pro Plus v6.0 image analysis system.

Western blot analysis involved extraction of general protein by conventional protein extraction kit (CWbio Co., Ltd., Beijing, China), BCA protein quantitation kit (Beijing ZS-Bio Co., Ltd.) testing, polyacrylamide gel electrophoresis (separation gel, stacking gel buffer, Beijing ZS-Bio Co., Ltd.), transmembrane (PVDF film; Millipore Corp., Billerica, MA, USA), closure, antibody incubation (first antibody is rabbit anti-rat PrP 1:2,000; FOXO 1:2,000; p-PI3K 1:1,000; p-Akt 1:1,000; GAPDH 1:500; second antibody is HRP-marked goat anti-rabbit, 1:500), developing and fixing, scanning and analyzing band density by using gel image analysis software, expressing relative content of target protein by using the ratio of target band and relevant GAPDH band signal intensity. The test was repeated 3 times and the average was calculated.

 Statistical analysis

SPSS 19.0 software (SPSS, Inc., Chicago, IL, USA) was utilized to analyze the data. Mean ± standard deviation was used to represent the quantitative data and comparisons among various groups were analyzed by one-way ANOVA, while the qualitative data were expressed by the number of cases, and inter-group comparison was tested by χ2. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Comparison of the level of serum IGF-1 and Aβ

The levels of IGF-1 and Aβ in group A were significantly higher than that in group B, which was significantly higher than that in groups C and D (P<0.05). The differences between groups C and D were not statistically significant (P>0.05; Table I).

 Comparison of tau protein phosphorylation level

The tau protein positive rate of group A was 75.6±20.3%, which was significantly higher than that of group B, 46.9±15.6%, which was significantly higher than that of groups C and D, 12.3±5.5 and 10.8±4.7%, respectively. The results were statistically significant (F=15.634, P<0.001). The difference between groups C and D were not statistically significant (P>0.05; Fig. 1).

 Comparison of the level of PrP, FOX protein, p-PI3K and p-Akt

The levels of PrP, FOX protein, p-PI3K and p-Akt of group A were significantly higher that of group B, which were significantly higher than that of groups C and D, and the results were statistically significant (P<0.05). The difference between groups C and D were not statistically significant (P>0.05; Table II and Fig. 2).

 Discussion

AD and Creutzfelt-Jakob disease (CJD) are neurodegenerative diseases that are caused by conformational change which result from the abnormal protein folding. In these diseases, normal and solvable protein transfers to unsolvable protein aggregation. In AD, this results in Aβ protein deposition and in CJD, this results in proteinase K resistant prion protein (PrPSc) deposition (6). It has been found that PrPs play an important role in the process where Aβ triggers AD (7). PrP, a highly conserved protein in animals, is highly expressed in the nervous system. In normal conditions, PrP is glycoprotein coded by the housekeeping gene and located on the surface of cell membranes. The change in natural conformation featuring rich α-spiral to the wrong conformation featuring rich β-folding (that is PrPC transferring to PrPSc) will lead to lethal neurodegenerative diseases such as CJD in mammals. The incidence of AD is accompanied by abnormal protein folding, conformational change, the formation of protein aggregation, and neuronal cell degeneration. Protein aggregation plays an important role in the death of cells (8). Currently, there are two opinions on the impact of PrP in the incidence of AD: One is that the PrP, as the membrane-anchored protein, functions as signal molecular receptor and triggers a pathway in the cell leading to toxicity by combining with Aβ oligomer outside the cell (9). The second opinion is that the PrP can impact Aβ formation, and is neuro-protective (10). In fact, the two functions can coexist and function in the body due to the PrP structural features and multi-functions resulted from the complexity of glycosylation.

IGF-1, made up of 70 amino acids and also known as sulphited factor and growth regulator C is a member of the insulin family. It has the function of stimulating the production, differentiation, migration, survival and metabolism. In recent years, IGF-1 has been found closely related to the central nervous system, especially to AD (11). IGF-1 functions through the IGF-1R, which is prevalent in the body. IGF-1R belongs to receptor tyrosine kinase family and is phosphorylated by IGF-1, which can activate insulin receptor substrate serial and other signal transduction pathways, including mitotic active protein kinase pathway, and PI3K/PKB pathway (12). IGF-1 plays a significant role in Aβ metabolism and tau protein phosphorylation. Adlerz et al (13) found that by stimulating α-secretase, IGF-1 decreased the formation of Aβ. Zhang et al (14) utilized PC12 cells and found that by stimulating α-secretase, IGF-1 decreased the formation of Aβ and that IGF-1 treatment can significantly decrease β-secretase (BACE-1) mRNA and protein levels and further decrease the formation of Aβ by using quantitative polymerase chain reaction (PCR) and western blot method for analysis of the results. This process was related to PI3K/Akt and MAPK/ERK1/2 signal pathways and the disorders of this signal system are involved in the formation of AD pathology. Wang et al (15) conducted IGF-1 intervention by using Aβ25–35 protein to induce injured PC12 cells to establish a cell model for over-phosphorylated tau proteins and found that IGF-1 can repress apoptosis of Aβ25-35-induced PC12 cells and tau protein phosphorylation, the action mechanism of which is activated through the signal transduction pathway.

FoxO family, a transcription factor, is a critical factor in INS/IGF-1 signal pathway. The upstream is adjusted by interconnected pathway of PI3K-PKB and the downstream adjusted target genes are mostly related to cell cycle, apoptosis, aging and metabolism (16).

FoxO phosphorylation/dephosphorylating status is closely related to the transcription adjustment function. FoxO transcription activeness is subjected to adjustment of the complex signal pathway. There are mainly two types of FoxO transcription activeness adjusted by phosphorylation: one is PI3 relying on pathway for phosphorylation adjustment and the other is non-PI3 relying on pathway for phosphorylation adjustment. PI3K/Akt/FoxO is a verified signal pathway (17). Insulin, IGF-1 and other growth factors combine with tyrosine kinase receptor to activate PI3K. Then Akt, including protein kinase of Akt family and relevant serum and glucocorticoid, induces the activation of SGK. RT-PCR and northern blot display that FoxO transcription factor is highly expressed in tissues and organs of adults, including in the heart and brain (18). In recent years, the study on FoxO action mechanism has gradually transferred from tumor cells to neuronal cells and it was found that when PI3K/Akt is activated, it can phosphorylate and deacetylate under the control of Sirt1, which enhanced the survival and production of neuronal cells (19). When the PI3K/Akt pathway is repressed, it can dephosphorylate and acetylate under the control of P300, inducing neuronal cell apoptosis (20). Dick and Bading (21) reported that the neuronal cells in CA1 area of hippocampus in particular is extremely prone to damage, which is related to the highly expressed FoxO transcription factors in CA1 area (21).

It is concluded from the present study that the level of IGF-1 and Aβ, tau protein positive rate, and the level of PrP, FOXO protein, p-PI3K and p-Akt of group A is significantly higher than that of group B, which is higher than that of groups C and D, and the results are statistically significant. The difference between groups C and D is not statistically significant. In summary, IGF-1 is highly expressed in senior patients with diabetes and dementia and it can adjust the expression of PrP and FOXO through p-PI3K/Akt pathway and further impact the formation of Aβ and tau protein, leading to dementia.

 References VerdelhoAMadureiraSMoleiroCFerroJMSantosCOErkinjunttiTPantoniLFazekasFVisserMWaldemarGLADIS study: White matter changes and diabetes predict cognitive decline in the elderly: The LADIS studyNeurology75160167201010.1212/WNL.0b013e3181e7ca0520625169 RasgonNJarvikLInsulin resistance, affective disorders, and Alzheimer's disease: Review and hypothesisJ Gerontol A Biol Sci Med Sci59178183discussion 184–192200410.1093/gerona/59.2.M17814999034 FreudeSSchilbachKSchubertMThe role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: From model organisms to human diseaseCurr Alzheimer Res6213223200910.2174/15672050978848652719519303 WhiteMFRegulating insulin signaling and beta-cell function through IRS proteinsCan J Physiol Pharmacol84725737200610.1139/y06-00816998536 JeongHJJeongHWSongSSKangJWSeoJHLeeYHLeeKSKimDWUpregulation of peroxiredeoxin III in the hippocampus of acute immobilization stress model rats and the Foxo3a-dependent expression in PC12 cellsCell Mol Neurobiol3110411046201110.1007/s10571-011-9703-421562855 ZhaoWQDe FeliceFGFernandezSChenHLambertMPQuonMJKrafftGAKleinWLAmyloid beta oligomers induce impairment of neuronal insulin receptorsFASEB J22246260200810.1096/fj.06-7703com17720802 RoychaudhuriRYangMHoshiMMTeplowDBAmyloid beta-protein assembly and Alzheimer diseaseJ Biol Chem28447494753200910.1074/jbc.R80003620018845536 HaassCSelkoeDJSoluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptideNat Rev Mol Cell Biol8101112200710.1038/nrm210117245412 BateCWilliamsAAmyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteinsJ Biol Chem2863795537963201110.1074/jbc.M111.24872421900234 CramerPECirritoJRWessonDWLeeCYKarloJCZinnAECasaliBTRestivoJLGoebelWDJamesMJApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse modelsScience33515031506201210.1126/science.121769722323736 DeochandCTongMAgarwalARCadenasEde la MonteSMTobacco smoke exposure impairs brain insulin/IGF signaling: Potential co-factor role in neurodegenerationJ Alzheimers Dis50373386201510.3233/JAD-150664 MoloneyAMGriffinRJTimmonsSO'ConnorRRavidRO'NeillCDefects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signallingNeurobiol Aging31224243201010.1016/j.neurobiolaging.2008.04.00218479783 AdlerzLHolbackSMulthaupGIverfeldtKIGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathwaysJ Biol Chem2821020310209200710.1074/jbc.M61118320017301053 ZhangHGaoYDaiZMengTTuSYanYIGF-1 reduces BACE-1 expression in PC12 cells via activation of PI3-K/Akt and MAPK/ERK1/2 signaling pathwaysNeurochem Res364957201110.1007/s11064-010-0260-x20821260 WangPJZhangYSongRRShenDFStudy of the protection and mechanism of IGF-1 on tau protein hyperphosphorylation in PC12 cells induced by Abeta(1–40)Sichuan Da Xue Xue Bao Yi Xue Ban419609642010(In Chinese)21265094 PuigOMarrMTRuhfMLTjianRControl of cell number by Drosophila FOXO: Downstream and feedback regulation of the insulin receptor pathwayGenes Dev1720062020200310.1101/gad.109870312893776 KimSJWinterKNianCTsuneokaMKodaYMcIntoshCHGlucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expressionJ Biol Chem2802229722307200510.1074/jbc.M50054020015817464 AcciliDArdenKCFoxOs at the crossroads of cellular metabolism, differentiation, and transformationCell117421426200410.1016/S0092-8674(04)00452-015137936 ZhaoXGanLPanHKanDMajeskiMAdamSAUntermanTGMultiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: Characterization of phosphorylation- and 14-3-3-dependent and -independent mechanismsBiochem J378839849200410.1042/bj2003145014664696 BrunetASweeneyLBSturgillJFChuaKFGreerPLLinYTranHRossSEMostoslavskyRCohenHYStress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylaseScience30320112015200410.1126/science.109463714976264 DickOBadingHSynaptic activity and nuclear calcium signaling protect hippocampal neurons from death signal-associated nuclear translocation of FoxO3a induced by extrasynaptic N-methyl-D-aspartate receptorsJ Biol Chem2851935419361201010.1074/jbc.M110.12765420404335

Immunohistochemical staining of tau protein (magnification, ×400).

Western blot analysis. PrP, prion protein; FOX, forkhead box.

Comparison of the level of IGF-1 and Aβ.

Group IGF-1, ng/ml Aβ, pg/ml
A 160.3±42.1 268.7±78.5
B 113.4±34.6 184.7±62.3
C 94.7±25.8 105.6±41.4
D 82.6±20.3 112.5±50.6
F-value 10.325 22.624
P-value <0.001 <0.001

Group A, senior patients with diabetes and dementia; group B, senior patients with dementia but no diabetes; group C, senior patients with diabetes but no dementia; group D, healthy seniors. IGF-1, insulin-like growth factor-1; Aβ, β-amyloid peptide.

Comparison of the level of PrP, FOX protein, p-PI3K and p-Akt.

Group PrP FOXO p-PI3K p-Akt
A 0.63±0.07 0.74±0.08 0.82±0.06 0.76±0.05
B 0.44±0.05 0.48±0.06 0.53±0.07 0.50±0.06
C 0.18±0.03 0.20±0.04 0.21±0.05 0.19±0.04
D 0.15±0.03 0.17±0.03 0.16±0.04 0.15±0.03
F-value   9.637   8.457 13.265 11.527
P-value <0.001 <0.001 <0.001 <0.001

PrP, prion protein; FOX, forkhead box.